Skip to main content

Table 2 Univariate analysis of variables predictive of PFS and OS

From: Nomograms based on SUVmax of 18F-FDG PET/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer/T-cell lymphoma

  PFS OS
Variables HR (95% CI) P value HR (95% CI) P value
Sex (Male vs. Female) 1.273 (0.831–1.948) 0.267 0.917 (0.541–1.555) 0.747
Age (≤60 vs. > 60) 1.470 (0.843–2.565) 0.174 1.296 (0.658–2.553) 0.453
Ann Arbor stage   < 0.001   < 0.001
 I Reference   Reference  
 II 1.894 (1.072–3.348) 0.028 2.123 (1.027–4.390) 0.042
 III-IV 3.843 (2.247–6.573) < 0.001 4.998 (2.551–9.791) < 0.001
Primary site (UADT vs. Extra-UADT) 1.388 (0.754–2.554) 0.292 1.612 (0.818–3.179) 0.168
B symptoms (No vs. Yes) 1.703 (1.109–2.616) 0.015 1.778 (1.055–2.995) 0.031
LDH (Normal vs. Elevated) 3.014 (1.928–4.711) < 0.001 3.923 (2.267–6.791) < 0.001
β2-MG (Normal vs. Elevated) 2.486 (1.639–3.772) < 0.001 2.788 (1.687–4.609) < 0.001
Hb (≥120 g/L vs < 120 g/L) 2.157 (1.388–3.352) < 0.001 1.879 (1.110–3.182) 0.019
SUVmax (≤9.5 vs. > 9.5) 2.971 (1.824–4.839) < 0.001 4.033 (2.088–7.791) < 0.001
Interim DS (1–3 vs. 4–5) 2.738 (1.393–5.379) 0.003 3.436 (1.554–7.595) 0.002
End-of-treatment DS (1–3 vs. 4–5) 6.707 (2.234–20.14) < 0.001 5.237 (1.412–19.43) 0.007
  1. Abbreviations: CI confidence interval, HR hazard ratio, PFS progression-free survival, OS overall survival, UADT upper aerodigestive tract, LDH lactate dehydrogenase, β2-MG β2-microglobulin, Hb hemoglobin, DS Deauville score
\